The cost of delay isn't theoretical
Every day a clinical study report sits in drafting is a day a sponsor is paying patent-protected revenue forward to a competitor. Industry benchmarks put the cost of delay for a typical phase 3 program at roughly $1.4M per day. And yet medical writers — the people closest to that critical path — spend the majority of their project time not interpreting science, but reformatting tables, chasing cross-references, and stitching together text from prior submissions.
That is the gap regulatory writing has lived inside for years. The science is hard. The writing should be the easy part. Instead, the writing has quietly become the bottleneck.
Why generic AI tools haven't moved the needle
The first wave of AI in regulatory writing — chat assistants, generic copilots, retrieval-augmented chatbots — promised to compress drafting time. In practice, three things have kept those tools from being adopted at scale:
- No provenance. A regulator cannot accept "the model said so." Every claim in a CSR, PSUR, or CMC module needs to point back to a specific table, figure, or paragraph in a source document. Generic AI tools either cite nothing, or cite hallucinated references.
- No document model. Regulatory documents have structure — section dependencies, conventions for how a safety summary relates to its narratives, ICH guidance on what belongs where. A general-purpose LLM treats a CSR as a long string of text. It is not.
- No workflow fit. Writing happens inside Word, against templates, with comments and tracked changes. A tool that lives in a separate browser tab adds a workflow step instead of removing one.
The result has been a lot of pilots, a lot of demos, and very little change in how regulatory documents actually get written.
What "agentic" means here, specifically
The shift we're seeing in 2026 isn't about a smarter chatbot. It's about treating regulatory writing as an agentic problem: a system that understands the document it is producing, plans the work in writer-defined sections, retrieves evidence from the writer's specified sources, and produces a draft with full provenance — every sentence linked back to the file, page, and span that grounds it.
That changes the writer's job from assembler to reviewer. The mechanical work compresses. The scientific judgment expands.
What's in the whitepaper
In our full whitepaper we lay out:
- Why the FDA's evolving stance on AI in regulatory submissions matters for sponsors choosing tooling now
- A side-by-side comparison of generic AI assistants vs. purpose-built agentic systems on the dimensions that actually matter for review
- The citation architecture required for a draft to survive a regulator's audit
- How "anticipating the FDA" — surfacing review questions before submission — changes pre-submission strategy
If you write, review, or commission regulatory documents, the whitepaper is the long-form version of the case for why this generation of tooling is fundamentally different from the last.